Plain-English translation of NCT07523880 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Patients with coronary heart disease who take blood-thinning medications face two serious risks: dangerous blood clots and major bleeding. This study is collecting blood samples and medical information from thousands of heart disease patients to discover new biological markers that can better predict who is at risk for these complications. Researchers will then use artificial intelligence to build improved prediction tools that help doctors choose the safest and most effective treatment for each patient.
Current tools for predicting blood clots and bleeding in heart disease patients are not accurate enough. This study aims to fill that gap by discovering new biological signals in blood and combining them with patient data and imaging to create much more precise risk prediction models, ultimately helping doctors prevent serious complications and personalize treatment.
You likely qualify if…
You likely don't qualify if…
If you join from an existing patient database, researchers will use your medical records and previous blood samples (with your permission) that have already been collected. If you are newly enrolled, you will provide written consent, donate blood samples at your initial visit, and then be contacted periodically over time to track whether you experience any blood clots or bleeding complications. The study involves no new medications or procedures — only careful monitoring and data collection to help improve future heart disease care.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
China